Prevnar 13

E474933

Prevnar 13 is a pneumococcal conjugate vaccine that protects against 13 serotypes of Streptococcus pneumoniae, helping prevent invasive pneumococcal disease and pneumonia, especially in children and older adults.

Try in SPARQL Jump to: Statements Referenced by

Statements (49)

Predicate Object
instanceOf pneumococcal conjugate vaccine
vaccine
administeredByRoute intramuscular injection
approvedBy U.S. Food and Drug Administration NERFINISHED
approvedIn European Union NERFINISHED
United States NERFINISHED
ATCCode J07AL02
containsAntigenType polysaccharide
containsCarrierProtein CRM197 NERFINISHED
developedBy Wyeth Pharmaceuticals NERFINISHED
dosageForm suspension for injection
firstApprovedYear 2009
hasGenericName pneumococcal 13-valent conjugate vaccine
hasManufacturer Pfizer NERFINISHED
indicatedFor adults 18 years and older with certain risk factors
adults 50 years and older
children
infants
older adults
isConjugatedTo CRM197 diphtheria protein NERFINISHED
marketedAs Prevenar 13 NERFINISHED
prevents invasive pneumococcal disease
pneumococcal pneumonia
protectsAgainst Streptococcus pneumoniae NERFINISHED
protectsAgainstSerotype 1
14
18C
19A
19F
23F
3
4
5
6A
6B
7F
9V
protectsAgainstSerotypeCount 13
recommendedBy Advisory Committee on Immunization Practices NERFINISHED
World Health Organization NERFINISHED
recommendedIn childhood immunization schedule
replacedProduct Prevnar NERFINISHED
replacedValent 7-valent pneumococcal conjugate vaccine
storageTemperature 2-8 °C
targetPathogen Streptococcus pneumoniae NERFINISHED
targetPopulation immunocompetent children
immunocompromised individuals at risk for pneumococcal disease
usedFor pneumococcal disease prevention
valency 13-valent

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Pfizer developed Prevnar 13